Apexigen Inc
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
MPW Medical Properties Trust Inc
MKSI MKS Instruments Inc
TPZ Tortoise Power and Energy Infrastructure Fund
NYC American Strategic Investment Co
MDV Modiv Inc
SBIG springbig Holdings Inc
KBNT Kubient Inc
FGF FG Financial Group Inc
NVNO enVVeno Medical Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Closing Price: $0.54

Day's Change: 0.042 (8.43%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.5802

Day's Low: 0.4713

Volume (Light) Volume: 904,162 10-day average volume: 1,183,003: 904,162

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.